baber/WOPTO huggingface dataset:
Patent NZ-248357-A (NZ)
Title: 7-(substituted)-9-[(substituted glycyl)- amido]-6-demethyl-6-deoxytetracyclines, preparation and pharmaceutical/veterinary compositions thereof
Inventor: SUM PHAIK-ENG
IPC: C07C/
Filed: 1993-08-09
Abstract: The invention provides compounds of the formula: <CHEM> wherein R, R<3>, R<4> and W are defined in the specification. These compounds are useful as antibiotic agents.
Patent NZ-252559-A (NZ)
Title: Antibodies or derivatives thereof to vitamin b12/transcobalamin ii receptor and use in preventing cellular uptake of vitamin b12 and inhibiting cell division
Inventor: MORGAN ALTON CHARLES
IPC: A61K38/00
Filed: 1993-05-07
Abstract: There is disclosed anti-receptor and growth blocking agents to the vitamin B12/transcobalamin II receptor and binding sites. The anti-receptor and growth blocking agents antagonize or modulate the vitamin B12/transcobalamin II receptor or binding sites, causing cellular depletion of vitamin B12, thus preventing or inhibiting cell division or causing apoptosis. Anti-receptor and growth blocking agents of the present invention include proteins (such as antibodies and antibody derivatives), peptides and small organic molecules. In a preferred embodiment, the anti-receptor agent is an antibody to the vitamin B12/transcobalamin II receptor.
Patent NZ-258012-A (NZ)
Title: Unit dose form (tablet or capsule) which releases a plurality of pellets each of which releases its active agent at different times by virtue of a different choice of coating agents and permeability reducing agent for each pellet
Inventor: CHEN CHIH-MING
IPC: A61K9/50
Filed: 1993-11-02
Abstract: PCT No. PCT/US93/10643 Sec. 371 Date Aug. 16, 1994 Sec. 102(e) Date Aug. 16, 1994 PCT Filed Nov. 2, 1993 PCT Pub. No. WO94/12160 PCT Pub. Date Jun. 9, 1994.Unit dosage form for delivering drugs into the body in a series of sequential, pulsatile releasing events employs conventional pharmaceutical equipment and processes for optimum economy, reliability, and bioavailability. The system can be used with drugs which cannot be released by diffusion through a porous coating, such as water insoluble drugs. A plurality of populations of pellets is provided within a unit dosage form such as a capsule (8) or tablet. The pellets are composed of a core containing the drug (3) and a swelling agent (4) which expands in volume when exposed to water. The core is enclosed within a membrane or coating which is permeable to water. The membrane is composed of a water insoluble and permeable film forming polymer, a water soluble film forming polymer (11) and a permeability reducing agent (14). When the unit dose releases the pellets into the digestive tract, water diffuses through the coating and into the core. As water is taken up by the swelling agent, the core expands, exerting force on the coating until it bursts, releasing the drug. The permeability reducing agent reduces the rate at which water reaches the swelling agent, thereby delaying release time. The water soluble polymer dissolves, weakening the coating so that it bursts sooner. By varying the proportions of the three coating ingredients and/or coating thickness from one pellet population to another, the release timing of the pellets can be very effectively controlled.
Patent NZ-268659-A (NZ)
Title: Vitamin d analogues containing an azide or 1,2,3-triazole group, pharmaceutical compositions
Inventor: HESSE ROBERT HENRY
IPC: A61P25/28
Filed: 1994-07-22
Abstract: The present invention relates to novel 1 alpha -hydroxy vitamin D derivatives in which the 17-position side chain carries an azide or optionally substituted 1,2,3-triazole group, including compounds of general formula (I) where R1 represents a methyl group having  alpha - or  beta -configuration; W represents a valence bond or a C1-5 alkylene group; X represents azide or an optionally substituted triazole group; and A= represents a cyclohexylidene moiety characteristic of the A-ring of a 1 alpha -hydroxylated vitamin D or analogue thereof. Active compounds of the invention exhibit cell modulating activity while exhibiting a substantial lack of calcaemic effect.
Patent NZ-331958-A (NZ)
Title: Improving corrosion resistance of metal surface, coating with thin layer of metal and annealing in inert atmosphere
Inventor: ALSTRUP IB
IPC: C23F15/00
Filed: 1998-09-17
Abstract: A method for enhancing the protection of high temperature alloys containing iron, nickel and chromium against high temperature corrosion by carburization or metal dusting comprising:   (a) deposition of a thin layer of a metal selected from one or more of the noble metals, precious metals, metals from group IV and group V of the Periodic Table and mixtures thereof with a thickness in the range 0.01 to 10  mu m on the surface to be protected. (b) annealing of the treated surface in an inert atmosphere at a predetermined temperature for a sufficient time.
Patent NZ-332526-A (NZ)
Title: Saw arbor with splined mandrel and mating internally and externally splined saw blade mounting sleeve
Inventor: VALLANCE LARRY DONALD
IPC: B27B5/34
Filed: 1997-08-29
Abstract: A saw arbour includes a splined mandrel 10 and a sleeve 22.  The sleeve has internal and external splines.  A saw blade 38 has a splined eye which matches the external splines on the sleeve.  All the splines are shaped so that the mating component can be slid onto the splines.  The numbers of splines on mandrel, sleeve and blade may be equal.
Patent NZ-336806-A (NZ)
Title: A thermionic generator fabricated by micromachining techniques
Inventor: EDELSON JONATHAN SIDNEY
IPC: G21H1/10
Filed: 1997-12-19
Abstract: A thermionic converter is fabricated by micro-machining techniques on one or more electrodes 1.  One or more electrodes 1 has on one face, a shallow depression of uniform depth.  The depression is coated by a thermionic material 8 which may be cesium, molybdenum, nickel, platinum, tungsten, cesiated tungsten, bariated tungsten, thoriated tungsten, the rare earth oxides such as barium and strontium oxides and carbonaceous materials such as diamond or sapphire.
Patent NZ-501787-A (NZ)
Title: Frozen dessert comprising ice cream containing probiotic lactic acid bacteria and a support free of bacteria containing fermentable fibres
Inventor: LESENS CORINNE
IPC: A23L29/20
Filed: 1998-06-12
Abstract: The composite frozen dessert comprises: i) an ice cream containing live or viable probiotic lactic acid bacteria and ii) an edible support substantially free of lactic acid bacteria, in which the support is a coating or a bakery or pastry item and comprises fermentable fibres specifically promoting growth, in the intestinal tract, of the probiotic lactic acid bacteria contained in the ice cream. Also described is the use of the (above described) frozen dessert in the manufacture of a medicament in the form of a composite frozen dessert for the treatment and/or prevention of gastrointestinal disorders, for strengthening the human immune system, or for increasing the absorption of minerals.
Patent NZ-506062-A (NZ)
Title: Dual polarisation patch antenna characterised by first and second pair of orthogonally disposed probes feeding a patch network wherein the first feed path feeds in two probes with one patch going through a stub element so as to cause cancellation of the first feed path
Inventor: ROBERTS ARTHUR GEORGE
IPC: H01Q21/06
Filed: 2000-07-31
Abstract: A feed network for a dual polarization network patch (20) antenna fed by probes (21), (22), (23) and (24). The feed network for the first polarization comprises a first feed path (26) from the feed point (25) to probe (21) and a second feed path (27) from the feed point (25) to probe (23). Feed path (27) includes a half wavelength section (28) so that the signals provided to probes (21, 23) are 180o out of phase at the central operating frequency. Feed path (26) further includes two quarter-wave separated open half-wavelength stubs (29). These are frequency dependent elements which alter the phase of signals conveyed via feed path (26) in dependence upon frequency. The bandwidth for which isolation is below -30 dB is over four times greater with stubs (solid lines) than without (dashed lines).
Patent NZ-506914-A (NZ)
Title: Optical translation measurement
Inventor: KINROT OPHER
IPC: G06F3/033
Filed: 1999-03-09
Abstract: A method for determining the relative motion of a surface with respect to a measurement device comprising: illuminating the surface with incident illumination; detecting illumination reflected from the surface to form at least one detected signal; and determining the amount of relative motion parallel to the surface from the detected signal.  The determining includes correcting for the effects of relative motion perpendicular to the surface.
Patent NZ-510094-A (NZ)
Title: Safe opening can end with a central lid portion having a bottom fold that extends radially beyond the score line that renders the severed edge safe
Inventor: HUBER WILLIAM
IPC: B21D51/38
Filed: 1999-08-09
Abstract: A safe container end closure includes an annular central lid portion, an annular peripheral lid portion, and a score line joining the annular central lid portion to the annular peripheral lid portion to permit removal of the central lid portion from the peripheral lid portion. A opening tab is secured to the central lid portion for pivoting movement relative to the central lid portion, with the opening tab having a nose positioned adjacent the score line so that upon pivoting of the opening tab the nose of the opening tab causes a portion of the score line to sever. The closure is formed so that upon removal of the central lid portion, at least the sharp edge on the removed central lid portion is rendered safe. The central lid portion thus includes an outwardly opening intermediate fold and an inwardly opening bottom fold, with the bottom fold extending radially outwardly beyond the score line so that when the central lid portion is separated from the peripheral lid portion at the score line the severed edge on the central lid portion is positioned radially inwardly of the radially outermost portion of the bottom fold. In addition, The score line is in the form of a V-shaped groove having a rounded nose that provides a variety of advantages. The closure also includes a nose spread below the score line defining the extent to which the severed edge of the central lid portion can move. The nose spread in the area of the nose of the opening tab is greater than at other areas along the circumferential extent of the central lid portion
Patent NZ-510154-A (NZ)
Title: A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
Inventor: ITOH KYOGO
IPC: C12P21/02
Filed: 1999-08-27
Abstract: A tumour antigen protein and gene therefor, tumour antigen peptides derived from the tumour antigen protein or derivatives thereof as well as medicaments, prophylactics, or diagnostics for tumours using such tumour substances in vitro or in vitro are provided.
Patent NZ-510331-A (NZ)
Title: Non-endogenous, constitutively activated human G protein-coupled receptors
Inventor: BEHAN DOMINIC P
IPC: C07K14/72
Filed: 1999-10-12
Abstract: Disclosed are constitutively activated, non-endogenous versions of endogenous human G protein-coupled receptors comprising (a) the following amino acid sequence region (C-terminus to N-terminus orientation) and/or (b) the following nucleic acid sequence region (3' to 5' orientation) transversing the transmembrane-6 (TM6) and intracellular loop-3 (IC3) regions of the GPCR: (a) P1 AA15 X and/or (b) Pcodon (AA-codon)15 Xcodon, respectively. In a most preferred embodiment, P1 and Pcodon are endogenous proline and an endogenous nucleic acid encoding region encoding proline, respectively, located within TM6 of the non-endogenous GPCR; AA15 and (AA-codon)15 are 15 endogenous amino acid residues and 15 codons encoding endogenous amino acid residues, respectively; and X and Xcodon are non-endogenous lysine and a non-endogenous nucleic acid encoding region encoding lysine, respectively, located within IC3 of the non-endogenous GPCR. As it is most preferred that the non-endogenous human GPCRs which incorporate these mutations are incorporated into mammalian cells and utilised for the screening of the candidate compounds, the non-endogenous human GPCR incorporating the mutation need not be purified and isolated per se (i.e., these are incorporated within the cellular membrane of a mammalian cell), although such purified and isolated non- endogenous human GPCRs are well within the purview of this disclosure.
Patent NZ-511048-A (NZ)
Title: Sanitary waste disposal unit
Inventor: CLARKE HOWARD MORGAN
IPC: F23G5/02
Filed: 1999-10-07
Abstract: A sanitary waste disposal unit (1) including a sealable destruction  chamber (11), a vacuum pump (23), a  source  of heat (15) and means (29) for the controlled introduction  of air  into  the chamber (11). In use the waste is  introduced on  the  chamber  (11), which is then  evacuated  to  remove substantially  all the oxygen, and heated to  sterilise  the waste  material  to approximately 300-500 °C.   The  chamber (11)  is  then cooled to approximately 150 °C,  a  temperate sufficiently  high enough to allow combustion of  the  waste material,  which has been partially carbonised.   A  limited quantity  of  air  is introduced into the  chamber  allowing combustion   of  the  waste  material  and  the   combustion products are removed from the chamber.
Patent NZ-511450-A (NZ)
Title: Method of identifying compounds that modulate the function of the human hypoxia-inducible factor 1-alpha (HIF-1alpha) functional domain
Inventor: BERKENSTAM ANDERS
IPC: A61K38/00
Filed: 1999-11-11
Abstract: Described is a method for identifying compounds capable of modulating the function of a functional domain of human HIF-1 alpha; the method comprising (i) contacting a candidate compound with a variant of human HIF-1 alpha, the variant essentially lacking at least one functional domain of human HIF-1 alpha, or having a mutation making at least one functional domain of human HIF-1 alpha essentially inactive.  The functional domain or domains being selected from the group consisting of (a) the PAS-B domain located in human HIF-1 alpha between amino acids 178 and 390, (b) the C-terminal nuclear localisation sequence (NLS) located in human HIF-1 alpha at amino acids 718 to 721, and (c) the transactivator/coactivator domain (N-TAD) located in human HIF-1 alpha between amino acids 531 to 584, and (d) the transactivator/coactivator domain (C-TAD) located in human HIF-1 alpha between amino acids 813 and 826, and (ii) determining the effect of the candidate compound on the variant.
Patent NZ-511516-A (NZ)
Title: A dual phase dentifrice composition in physically separate compartments, the first dentifrice containing linear polyphosphates, the second containing stannous ions
Inventor: GLANDORF WILLIAM MICHAEL
IPC: A61K8/24
Filed: 1999-11-23
Abstract: Disclosed are methods for reducing the staining of a dentifrice composition containing stannous ions comprising administering to a subject the dentifrice composition.  The dentifrice composition is a dual phase dentifrice and is contained in physically separated compartments of a dentifrice dispenser.  The first dentifrice composition comprises an effective amount of one or more linear polyphosphates having an average chain length of about 4 or more and has a total water content of up to about 20%.  The second dentifrice composition comprises an effective amount of stannous ions.  The molar ratio of polyphosphate anion to stannous ion is from about 0.2:1 to about 5:1 and the efficacy of the stannous ion in the dentifrice is not reduced by the polyphosphate. The dentifrice composition may alternatively be a single-phase dentifrice.  The single-phase dentifrice will comprise an effective amount of one or more linear polyphosphates having an average chain length of about 4 or more and an effective amount of a stannous anion.  The single phase dentifrice has a total water content of up to about 20%, the stannous ion is not delivered from stannous fluoride, a molar ratio of polyphosphate anion to stannous ion is from about 0.2:1 to about 5:1, and the efficacy of the stannous ion in the dentifrice is not reduced by the polyphosphate.
Patent NZ-514383-A (NZ)
Title: Process of preparing 3S-3-amino-3-aryl propionic acid and derivatives thereof
Inventor: SCOTT LORRAINE
IPC: C07D213/55
Filed: 2000-03-21
Abstract: A process for preparing a compound of formula (I) comprising reacting a compound of formula (II), at a pH range of between about 7 and about 11, to form a compound of formula (III) wherein R5 is N-t-butoxycarbonyl, reacting a compound of formula (III) with at least 0.5 equivalents of (lR, 2S)- (-) ephedrine, in an alkyl acetate solvent, to form a salt of formula (IV) wherein Ph is phenyl, reacting the salt of formula (IV) with an inorganic base in water to form a carboxylate salt of the compound of formula (V), acidifying the carboxylate salt of the compound of formula (V) with an acid of pKa less than or equal to three, to a pH of between about 3.5 and about 6.5, to form the compound of formula (V), reacting the compound of formula (V), at a temperature less than about25 C, to form the compound of formula (I).
Patent NZ-516673-A (NZ)
Title: Colour cosmetic selection system
Inventor: FLYNN MADELINE DEMAYO
IPC: A45D44/00
Filed: 2000-06-13
Abstract: A virtual makeover method is provided allowing a customer to select an optimum colour cosmetic palette through interaction with an Internet web site. The method includes downloading from the Internet web site a facial image which may be that of customers themselves, selection of a particular type of colour cosmetic, selection of a first colour from a palette of colours, application of the first colour to areas of the facial image and once the customer is satisfied with the colour selection, placement of an order for that cosmetic product appropriate to the area in the selected colour.
Patent NZ-518131-A (NZ)
Title: High performance cigarette filter with mechanical disintegratability based on cellulose ester, in particular cellulose acetate, fibres or filaments
Inventor: TEUFEL EBERHARD
IPC: A24D3/10
Filed: 2000-10-20
Abstract: Described is a high performance cigarette filter on the basis of cellulose ester fibres or filaments that can be mechanically disintegrated.  The high-performance cigarette filter is characterised in that a) the fibre weight (or filament weight)/draw resistance ratio S based on the filament titre is greater than approximately 0.7, the S value being calculated according to the formula S = (mA / ÄP7.8 / dpf [10 m/daPA], wherein mA refers to the fibre weight, ÄP refers to the draw resistance and dpf represents the filament titre and for the draw resistance the value calculated for a diameter of 7.8 mm is inserted, b) the residual crimping value of the filter material does not exceed the value 1.45, c) the fibre weight amounts to maximally 10 mg/mm of the filter length, and d) the hardness of the cigarette filter is higher than approximately 90% filtrona hardness. The distinegratability is thereby improved under environmental conditions vis-à-vis comparable products.
Patent NZ-518256-A (NZ)
Title: Modified peptides and peptidomimetics for use in immunotherapy
Inventor: TIMMERS CORNELIS MARIUS
IPC: A61K38/095
Filed: 2000-10-12
Abstract: Disclosed is a modified peptide derived from H-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-OH having general formula (II): Q-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-Z. In general formula (II), A1 through A13 correspond with the amino acids of formula (I), Q corresponds with H and Z corresponds with OH. The modifications according to the disclosed are selected from one or more of the groups a, b or c, consisting of a) substitution of 1-6, preferably 1-4 amino acids at A1 through A13 with non-natural amino acids or beta amino acids; b) substitution of one or more amide bonds with reduced amide bonds or ethylene isosteres; c) substitutions at Q and/or Z and, optionally, d) substitution of natural amino acids up to a total of 6 modifications. The peptides can be used for inducing tolerance induction in patients suffering from autoimmune diseases.
Patent NZ-522079-A (NZ)
Title: Method and composition for removing sodium-containing material from microcircuit substrates
Inventor: SCHWARTZKOPF GEORGE
IPC: C11D7/50
Filed: 2001-03-19
Abstract: An organic solvent-containing composition and its use by the application to surfaces, for inhibiting adsorption of sodium to integrated circuit surfaces during photoresist removal or post-metal etch cleanup is disclosed, wherein the composition comprises: 1,2-diaminocyclohexanetetracarboxylic acid (CYDTA), from 1-50% of a nucleophilic amine, and a non-nitrogen containing weak acid. Wherein the weak acid has a pK value of 2 or greater is in an amount sufficient to partially neutralize the nucleophilic amine such that the composition has an aqueous pH 9.6-10.9; the solvent is a stripping solvent system having a solubility of 8-15% and is present in an amount of 50-98% by weight of the composition.
Patent NZ-525565-A (NZ)
Title: Shoe sole structure
Inventor: WANG SWEI MU
IPC: A43B13/18
Filed: 2003-04-30
Abstract: A shoe sole structure that not only provides a shock absorbing effect but also can protect the elastic portion of the shoe sole structure from aging and wear. The shoe sole structure contains a first protective container (11), a first elastic pad (1), a second protective container (21) and a second elastic pad (2). The first protective container has a first side (14) having a first containing space and a second side (15) having plural first gutters (12) thereon. The first elastic pad is united with the first side within the first containing space. The second protective container has a third side (25) having a second containing space and a fourth side (26) having plural second gutters (22) thereon. The second side is united with the fourth side. Accordingly the first and second elastic pads are protected from exposure to sunlight and air directly and the first gutters combined with the second gutters form plural channels that greatly increase the elasticity of the shoe sole structure.
Patent NZ-528188-A (NZ)
Title: A process and plant for producing a milk or whey product having a reduced spores and bacteria content
Inventor: JENSEN JOHN
IPC: A23C9/142
Filed: 2001-02-15
Abstract: Disclosed is a process for the manufacture of a milk or whey product having a reduced spores and bacteria content, especially for the treatment of milk for the manufacture of standardized consumer milk or cheese milk and skim milk powder or whole milk powder, as well as a plant for carrying out the process. The invention enables the manufacture of the desired milk product using skim milk having a reduced content of microorganisms (spores and bacteria) relative to the prior art processes. Further more, the invention can be applied in connection with the manufacture of whey or pre-concentrated whey having a reduced spores and bacteria content. The first mentioned of these applications comprises a microfiltration of the skim milk fraction containing the microorganisms and fat in two steps whereby the first step produces a first permeate consisting of skim milk having a reduced content of microorganisms and fat and which is mixed with the sterilized cream fraction, the second step is fed with a retentate from the first step, and a second permeate generated in the second step is completely or partially recycled to the skim milk fraction at the inlet to the first step.